Sustainability at Biocon

Comprehensive portfolio of 20 biosimilars and vaccines... Biosimilar Product Status MoW4 Biocon Europe, CANZ Therapeutic Area Molecule US Dev. Markets: ex-US Pegfilgrastim¹ Trastuzumab¹ Oncology Bevacizumab¹ Immunology Diabetes Denosumab Pertuzumab 1 Adalimumab 1,2 Etanercept 1,2 Ustekinumab Glargine 100U 1,3 Glargine 300U¹ Aspart¹ Denosumab Europe, CANZ Europe, AU, CA Europe, CANZ, JP Europe, CA, JP Europe UK, CANZ, JP Europe, CANZ, JP Europe Europe, CA Europe, CANZ, JP Commentary bBevacizumab: Approved in EU, Canada and Australia; US approval awaiting site inspection b Denosumab: Ph-1 clinical trial on-going. Ph-3 planned start in Q1 FY'23 bAdalimumab: US launch expected in mid-2023 - bustekinumab: Ph-1 clinical trial on-going. Ph-3 clinical trial planned start in Q1 FY'23 rHI (US): BLA filing for various presentation rHI Bone Health 7 Assets Aflibercept Undisclosed Ophthalmology bAflibercept: First-to-file in US Early Dev./ Preclinical Clinical Filed Approved Access to SILS vaccine portfolio (Covishield and Covovax) and other next generation vaccines (e.g., mosquito-borne disease vaccines)6 1 In partnership with Viatris; 2 Partner Viatris has in-licensed product (Biocon benefits from economic interest) | 3 Japan is outside of Viatris partnership | 4 MoW represents Most of the World markets. Chart represents the status of the country where the product is in most advanced stage. Every country has a different status | 5 Expected to be included in BBL portfolio post the completion of BBL's acquisition of Viatris' biosimilar business (Viatris has global rights to the program partnered with Momenta) | 6 Subject to completion of the acquisition of Covishield Technologies Private Limited (CTPL) 20

View entire presentation